![You Can’t Make This Up podcast artwork](https://cdn.player.fm/images/21055062/series/xUxSMTjIutrzxfGp/32.jpg 32w, https://cdn.player.fm/images/21055062/series/xUxSMTjIutrzxfGp/64.jpg 64w, https://cdn.player.fm/images/21055062/series/xUxSMTjIutrzxfGp/128.jpg 128w, https://cdn.player.fm/images/21055062/series/xUxSMTjIutrzxfGp/256.jpg 256w, https://cdn.player.fm/images/21055062/series/xUxSMTjIutrzxfGp/512.jpg 512w)
![You Can’t Make This Up podcast artwork](/static/images/64pixel.png)
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers.
Quagliata discusses Thermo Fisher’s ongoing collaboration with EVERSANA, pharmaphorum’s parent company, and that collaboration’s investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company’s value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions.
That included a presentation at Frontiers Health 2024, in Berlin, in the deep dive, ‘Overcoming data linkage barriers with tokenization technology: RWE on the use of targeted therapy and its impact on survival in blood malignancies’ – presented alongside Dr Pierantonio Russo, Corporate Chief Medical Officer at EVERSANA.
227 episoade
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers.
Quagliata discusses Thermo Fisher’s ongoing collaboration with EVERSANA, pharmaphorum’s parent company, and that collaboration’s investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company’s value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions.
That included a presentation at Frontiers Health 2024, in Berlin, in the deep dive, ‘Overcoming data linkage barriers with tokenization technology: RWE on the use of targeted therapy and its impact on survival in blood malignancies’ – presented alongside Dr Pierantonio Russo, Corporate Chief Medical Officer at EVERSANA.
227 episoade
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.